Chemical formula: C₂₉H₃₁N₇O Molecular mass: 493.603 g/mol PubChem compound: 5291
Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr-Abl tyrosine kinase at the in vitro, cellular and in vivo levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01EA01 | Imatinib | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EA BCR-ABL tyrosine kinase inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| GILVEC Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| GLEEVEC Film coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Imatinib is an active ingredient of these brands:
United States (US)
Austria (AT)
Brazil (BR)Canada (CA)
Croatia (HR)
Ecuador (EC)Estonia (EE)Finland (FI)
France (FR)
Hong Kong (HK)Ireland (IE)
Israel (IL)
Japan (JP)
Lithuania (LT)Mexico (MX)
Netherlands (NL)
Nigeria (NG)
Poland (PL)Romania (RO)Singapore (SG)South Africa (ZA)Spain (ES)
Tunisia (TN)Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
